MedPharm names Bill Humphries as CEO to drive growth

U.K. – MedPharm has appointed Bill Humphries as its new CEO, signaling a key move in the company’s plans for strategic growth.

This leadership change comes after its merger with Tergus Pharma, a Great Point Partners portfolio company, in July 2024.

The merger strengthened MedPharm’s capabilities in clinical trial manufacturing, commercial production, and scientific expertise, positioning it for future expansion.

With over 36 years of experience in the pharmaceutical and life sciences industries, Humphries is set to lead MedPharm into its next stage of development.

He has a strong track record in business transformation and operational improvements, having served as CEO of Alcami, Isosceles Pharmaceuticals, and Merz North America.

Additionally, he has held leadership roles at major companies such as Ortho-Dermatologics, Stiefel, and Allergan Pharmaceuticals.

Humphries also brings extensive boardroom experience, having served as Clearside Biomedical’s chairman, STRATA Skin Sciences’ executive chairman, and a board member for companies like Aclaris Therapeutics, PhaseBio Pharmaceuticals, Bryn Pharmaceuticals, and SKNV.

Expressing his enthusiasm for the role, Humphries stated, “It is a privilege to join MedPharm and the team at this important period in its evolution and growth aspirations. I am excited to leverage my direct experience in the topical and transdermal space to accelerate MedPharm’s growth.

I believe MedPharm is well-positioned to serve clients across all channels in the topical space, and we look forward to delivering incremental value for trusted existing and new clients.”

MedPharm specializes in providing end-to-end contract services for topical and transepithelial products. Its offerings include early-phase research, in vitro testing services, clinical and commercial manufacturing, and formulation development.

The company operates facilities in the US and the UK, including a state-of-the-art 97,000-square-foot manufacturing site in Durham, North Carolina.

MedPharm is backed by investors Bourne Partners Strategic Capital, Great Point Partners, and Ampersand Capital Partners, ensuring solid financial support for its ambitious growth plans.